Manager TitleAgeSince
Chief Executive Officer 58 05/04/2023
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 45 -
Director TitleAgeSince
Director/Board Member 47 30/11/2021
Director/Board Member 52 13/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
10/04/23
5AM Venture Management LLC
SellCompany 16,544,113 11.8148%
15/02/23 Free

Chief Executive Officer

2,285,714 1.6323%
15/02/23 Free

Chief Technology Officer

1,333,333 0.9522%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 142
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-3.39%+2.17%+28.68%+21.82% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.86%-0.08%+53.10%+154.17% 44.09B
Weighted average by Cap. -0.43%+0.11%+57.76%+145.71%
Logo Pear Therapeutics, Inc.
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
Employees
200
  1. Stock Market
  2. Stocks
  3. PEAR Stock